Telomir Pharmaceuticals Announces Promising Preclinical Results

The latest update is out from Telomir Pharmaceuticals, Inc. ( (TELO) ).

On June 11, 2025, Telomir Pharmaceuticals announced promising preclinical results for its lead candidate, Telomir-1, in treating Wilson’s disease. The study showed significant improvements in neurological, liver, and kidney functions in an animal model, suggesting Telomir-1’s potential as a disease-modifying treatment. These findings support further development towards human trials, with plans for an IND submission by the end of the year and clinical trials in 2026.

The most recent analyst rating on (TELO) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Telomir Pharmaceuticals, Inc. stock, see the TELO Stock Forecast page.

More about Telomir Pharmaceuticals, Inc.

Telomir Pharmaceuticals, Inc. operates in the pharmaceutical industry, focusing on developing treatments for rare genetic disorders. The company is advancing its lead small molecule candidate, Telomir-1, targeting conditions like Wilson’s disease, which involves copper dysregulation.

Average Trading Volume: 197,048

Technical Sentiment Signal: Sell

Current Market Cap: $61.01M

For a thorough assessment of TELO stock, go to TipRanks’ Stock Analysis page.